Clinical Trials
13 trialsNCT06151847 2026-04-30
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Completed
NCT01416831 2026-04-24
SBRT/IL-2
Providence Health & Services
Phase 2 Active not recruiting
NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04562129 2026-04-01
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT00338377 2026-03-20
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07288073 2026-02-13
TIL Therapy in cSCC and MCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT01319565 2025-12-19
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01697527 2025-11-24
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06884670 2025-09-08
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT05080790 2025-08-17
DiTuSarc
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed